Ovarian cancer resistance under the microscope: 600-Patient study launches
NCT ID NCT03954171
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is looking at why some ovarian cancers become resistant to platinum-based chemotherapy, a common treatment. Researchers will collect blood, tumor, and fluid samples from 600 patients over five years, alongside their medical data. No new drugs are being tested—the goal is to gather information to better understand resistance and potentially improve future treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors predict or delay resistance to platinum chemotherapy in ovarian cancer patients.
- What could go wrong
- This is an observational study, not a treatment trial. It may not lead to any immediate changes in care, and results may take years to apply.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut Universitaire du Cancer de Toulouse - Oncopole
RECRUITINGToulouse, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Metabolic clues: could your Body's energy use predict ovarian cancer outcomes?
- Can heated chemo during surgery help older women with ovarian cancer?
- Can a custom mRNA vaccine keep ovarian cancer from coming back?
- Could centralized surgery boost ovarian cancer survival?
- Targeted drug hunts down cancer cells in advanced bladder cancer trial
- New PET tracer aims to spot hidden cancer spread in the abdomen